Torrent Pharma Delivers Robust Q2 FY26 Performance with 30% Profit Surge

Revenue Growth: Total revenue from operations reached ₹3,302 crore, up from ₹2,889 crore in Q2 FY25.
Profit Surge: Net profit climbed to ₹591 crore, a 30.5% YoY increase, driven by strong domestic and international performance.
EBITDA Performance: EBITDA rose 15.3% to ₹1,083 crore, with a stable operating margin of 32.8%.
India Market: Domestic revenue grew 12% to ₹1,820 crore, led by focus therapies and chronic portfolio outperformance.
International Markets: US: Revenue up 26% to ₹337 crore. Brazil: Revenue up 21% to ₹318 crore. Germany: Revenue up 5% to ₹303 crore, impacted by third-party supply disruptions.
R&amp;D Investment: R&amp;D spend increased 8% YoY to ₹156 crore, reinforcing innovation commitment.
Brand Strength: Torrent holds 21 brands in the Top 500 of the Indian Pharmaceuticals Market.

Updated: November 07, 2025 20:08

Image Source: Goodreturns

Torrent Pharma reported a 30.5% YoY rise in Q2 FY26 net profit to ₹591 crore, with revenue from operations up 14% to ₹3,302 crore. Strong growth in India, US, and Brazil markets, stable margins, and increased R&D investment highlight the company’s robust performance and strategic focus on core therapies.